Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Nov 12, 2015	Evoke Pharma Reports Third Quarter 2015 Results Enhanced Financial Strength and Further Progressed Trial Enrollment	View HTML Evoke Pharma Reports Third Quarter 2015 Results 26.1 KB
Toggle Summary Nov 10, 2015	Evoke to Participate in the Brean Capital 2015 Life Sciences Summit SOLANA BEACH, Calif. , Nov. 10, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer , R.Ph., President and CEO will be participating in the Brean Capital 2015 Life	View HTML Evoke to Participate in the Brean Capital 2015 Life Sciences Summit 15.3 KB
Toggle Summary Nov 05, 2015	Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results SOLANA BEACH, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results 11.9 KB
Toggle Summary Oct 07, 2015	Evoke Pharma Strengthens Financial Position Provides Additional Support for Completion of Phase 3 Trial and Submission of New Drug Application (NDA)	View HTML Evoke Pharma Strengthens Financial Position 16.9 KB
Toggle Summary Sep 28, 2015	Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 150 Patients Enrolled in Phase 3 Clinical Trial	View HTML Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 15.7 KB
Toggle Summary Sep 15, 2015	U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001 States Patients With Diabetic Gastroparesis May Have Unpredictable Gastric Emptying and Altered Absorption of Orally-Administered Hypoglycemic Drugs	View HTML U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001 18.7 KB
Toggle Summary Aug 18, 2015	Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 SOLANA BEACH, Calif. , Aug. 18, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating the agency's	View HTML Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 16.6 KB
Toggle Summary Aug 13, 2015	Evoke Pharma Reports Second Quarter 2015 Results Enrolled 130 total subjects in Phase 3 clinical trial through end of July Recent FDA draft guidance of advice on Gastroparesis mirrors Evoke's Phase 3 clinical trial protocol design SOLANA BEACH, Calif. , Aug. 13, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.	View HTML Evoke Pharma Reports Second Quarter 2015 Results 28.6 KB
Toggle Summary Jul 30, 2015	Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2015 Financial Results SOLANA BEACH, Calif. , July 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2015 on Thursday, August 13,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2015 Financial Results 13 KB
Toggle Summary Jul 01, 2015	Evoke Pharma to Present at Cantor Fitzgerald Inaugural Healthcare Conference SOLANA BEACH, Calif. , July 1, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Wednesday, July 8, 2015 at 10:15 AM ET at the Cantor Fitzgerald Inaugural	View HTML Evoke Pharma to Present at Cantor Fitzgerald Inaugural Healthcare Conference 14.8 KB